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Abstract
In addition to the monographs which have been published in
the past 4 years by the working group ‘‘Drug Monitoring’’
of the Swiss Society of Clinical Chemistry (SSCC) w1–4x,
new monographs have been written. The data presented in
these monographs provide an overview of important infor-
mation for the request and interpretation of results. There-
fore, laboratory health professionals and the receivers of the
reports are the targeted readers. In this series, several anti-
epileptic drugs are presented. Monographs on carbamazepine
w1x, lamotrigine w2x, phenobarbital w2x, and valproic acid w2x
have been published previously. First, information about
pharmacology and pharmacokinetics of these drugs (protein
binding, metabolic pathways and enzymes involved, elimi-
nation half-life time and elimination route(s) of the parent
drug and therapeutic as well as toxic concentrations) is
given. Second, the indications for therapeutic drug monitor-
ing are listed. Last but not least, important pre-analytical
information is provided, including time points of blood sam-
pling and time interval after which steady-state concentra-
tions are reached after changing the dose. Furthermore, the
stability of the drug and its metabolite(s) after blood sam-
pling is described. For readers with a specific interest, ref-
erences to important publications are given. The number of
the monographs will be further enlarged. The updated files
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are presented on the homepage of the SSCC (www.sscc.ch).
We hope that these monographs are helpful for the better
handling of therapeutic drug monitoring and we are looking
forward to comments from the readers.
Keywords: antiepileptics; clonazepam; ethosuximide; gaba-
pentine; levetiracetam; oxcarbazepine; phenytoin; primidone;
topiramate; vigabatrin.
Zusammenfassung
Erga¨nzend zu den in den letzten vier Jahren publizierten Arz-
neimittelmonographien der Arbeitsgruppe ,,Medikamente‘‘
der Schweizerischen Gesellschaft fu¨r Klinische Chemie
(SGKC) w1–4x, sind weitere Monographien erstellt worden.
Der Labormediziner bzw. der Empfa¨nger der Befunde soll
mit diesen Monographien eine U¨ bersicht u¨ber die wichtigs-
ten Informationen erhalten, die fu¨r die Veranlassung einer
Analyse bzw. fu¨r die Interpretation der Resultate hilfreich
sind. In dieser Serie werden verschiedene Antiepileptika pra¨-
sentiert. Die Monographien zu Carbamazepin w1x, Lamotri-
gin w2x, Phenobarbital w2x, und Valproinsa¨ure w2x wurden
bereits in fru¨heren Serien publiziert. Die einzelnen Mono-
graphien beinhalten einerseits Angaben zu klinisch-pharma-
kologischen Daten, wie zum Beispiel zu den Protein-
bindungen, Metabolisierungswegen und daran beteiligten
Enzymen, Halbwertzeiten und Eliminationswege der Mutter-
substanz sowie Informationen zu therapeutischen bzw. toxi-
schen Bereichen. Andererseits werden bei jeder Substanz die
Indikationen fu¨r das Therapeutic-Drug-Monitoring aufgelis-
tet und wichtige Angaben zur Pra¨analytik gemacht (Zeit-
punkt der Blutentnahme und Zeitpunkt des Erreichens einer
Steady-state-Situation nach einer Dosisa¨nderung). Außerdem
werden Angaben u¨ber die Stabilita¨t der Medikamente bzw.
ihrer Metaboliten nach der Blutentnahme gemacht. Fu¨r die
interessierten Leser sind die verwendeten Referenzen als
Zitate aufgefu¨hrt. Die Zahl der Monographien wird fortlau-
fend erga¨nzt. Die aktuellsten Versionen der Monographien
sind auf der Homepage der SGKC abrufbar (www.sscc.ch).
Wir hoffen, dass diese Monographien im Umgang mit dem
Therapeutic-Drug-Monitoring hilfreich sein werden und
freuen uns u¨ber Kommentare und Bemerkungen.
Schlu¨sselwo¨rter: Antiepileptika; Clonazepam; Ethosuximid;
Gabapentin; Levetiracetam; Oxcarbazepin; Phenytoin; Pri-
midon; Topiramat; Vigabatrin.
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Clonazepam
General
• Class of the drug: Antiepileptics
• Synonym(s):
• Common trade name(s) in Germany: Rivotril
• Conversion factors: mg/L=3.167snmol/L
nmol/L=0.316smg/L
Clinical pharmacology
• Indications for TDM: Individual dose adaptation, verification of compliance, side effects, suspicion of
toxicity
• Protein binding: 85%
• Elimination half-life: 20–60 h
• Volume of distribution: 3 L/kg
• Metabolism:
– Main metabolic pathways: CYP3A4
– Active metabolite(s)? 7-amino-clonazepam
– Inhibitor or inductor of the No
cytochrome P450 system?
– Other significant pharmacokinetic None
interactions:
• Elimination of parent drug: Hepatic
• Typical therapeutic range: 20–40 mg/L (63–127 nmol/L)
• Potentially toxic concentration: )100 mg/L ()316 nmol/L)
Pre-analytics
• Time to steady-state since beginning ;4–10 days
of treatment or change of posology:
• Time for blood sampling: Before next dose at steady-state
• Type(s) of sample: Serum or plasma
• Stability: 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2009.
• Badiu CI. Sensitivity of thalamic GABAergic currents to clonazepam does not
differ between control and genetic absence in epilepsy rats. Brain Res 2004;
1026:261–6.
• Winkler D, Willeit M, Wolf R, Stamenkovic M, Tauscher J, Pjrek E, et al.
Clonazepam in the long-term treatment of patients with unipolar depression
bipolar and schizoaffective disorder. Eur Neuropsychopharmacol 2003;13:129–
34.
• Wad N. Degradation of clonazepam in serum by light confirmed by means of
high performance liquid chromatographic method. Ther Drug Monit 1986;8:
358–60.
• Walson PD, Edge JH. Clonazepam disposition in pediatric patients. Ther Drug
Monit 1996;18:1–5.
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, et al.
The AGNP-TDM expert group consensus guidelines: therapeutic drug
monitoring in psychiatry. Pharmacopsychiatry 2004;37:246–65.
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Ethosuximide
General
• Class of the drug: Antiepileptics
• Synonym(s):
• Common trade name(s) in Germany: Petnidan, Suxilep
• Conversion factors: mg/L=7.082smmol/L
mmol/L=0.141smg/L
Clinical pharmacology
• Indications for TDM: Individual dose adaptation, verification of compliance, side effects, suspicion of
toxicity
• Protein binding: No
• Elimination half-life: 48–60 h
• Volume of distribution: 0.7 L/kg
• Metabolism:
– Main metabolic pathways: CYP3A
– Active metabolite(s)? No
– Inhibitor or inductor of the No
cytochrome P450 system?
– Other significant pharmacokinetic None
interactions:
• Elimination of parent drug: Mainly hepatic, 20% renal
• Typical therapeutic range: 40–100 mg/L (280–700 mmol/L)
• Potentially toxic concentration: )141 mg/L ()1000 mmol/L)
Pre-analytics
• Time to steady-state since beginning ;7–10 days
of treatment or change of posology:
• Time for blood sampling: Before next dose at steady-state
• Type(s) of sample: Serum or plasma
• Stability: 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2009.
• Pellock JM. Standard approach to antiepileptic drug treatment in the United
States. Epilepsia 1994;35(Suppl 4):S11–8.
• Loscher W, Schmidt D. Strategies in antiepileptic drug development: is rational
drug design superior to random screening and structural variation? Epilepsy Res
1994;17:95–134.
• Campbell DB. Stereoselectivity in clinical pharmacokinetics and drug
development. Eur J Drug Metab Pharmacokinet 1990;15:109–25.
• Sghendo L, Mifsud J, Ellul-Micallef R, Portelli J, Millership JS. A sensitive gas
chromatographic/mass spectrometric method for the resolution and
quantification of ethosuximide enantiomers in biological fluids. J Chromatogr B
2002;772:307–15.
132 Rentsch et al.: Monographs on drugs which are frequently analyzed in therapeutic drug monitoring
Article in press - uncorrected proof
Gabapentine
General
• Class of the drug: Antiepileptics
• Synonym(s):
• Common trade name(s) in Germany: Neurontin
• Conversion factors: mg/L=5.840smmol/L
mmol/L=0.171smg/L
Clinical pharmacology
• Indications for TDM: Individual dose adaptation, verification of compliance, side effects, suspicion of
toxicity
• Protein binding: No
• Elimination half-life: 5–15 h
• Volume of distribution: 58 L/kg
• Metabolism:
– Main metabolic pathways: No metabolites identified
– Active metabolite(s)? No
– Inhibitor or inductor of the No
cytochrome P450 system?
– Other significant pharmacokinetic None
interactions:
• Elimination of parent drug: Renal
• Typical therapeutic range: 1.7–20.5 mg/L (10–120 mmol/L)
• Potentially toxic concentration: Not known
Pre-analytics
• Time to steady-state since beginning of ;30 h
treatment or change of posology:
• Time for blood sampling: Before next dose at steady-state
• Type(s) of sample: Serum or plasma
• Stability: 1 week at 48C
Remarks Nonlinear kinetics of absorption
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2009.
• Tomson T, Johanessen SI. Therapeutic monitoring of the new antiepileptic drugs.
Eur J Clin Pharmacol 2000;55:697–705.
• Patsalos PN. New antiepileptic drugs. Ann Clin Biochem 1999;36:10–9.
• Jiang Q, Li S. Rapid high-performance liquid chromatographic determination of
serum gabapentin. J Chromatogr B 1999;727:119–23.
• Gauthier D, Gupta R. Determination of gabapentin in plasma by liquid
chromatography with fluorescence detection after solid-phase extraction with a
C18 column. Clin Chem 2002;48:2259–61.
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Levetiracetam
General
• Class of the drug: Antiepileptics
• Synonym(s):
• Common trade name(s) in Germany: Keppra
• Conversion factors: mg/L=5.875smmol/L
mmol/L=0.1702smg/L
Clinical pharmacology
• Indications for TDM: Individual dose adaptation, verification of compliance, side effects, suspicion of
toxicity
• Protein binding: -10%
• Elimination half-life: 6–8 h
• Volume of distribution: 0.5–0.7 L/kg
• Metabolism:
– Main metabolic pathways: Enzymatic hydrolysis in blood
– Active metabolite(s)? No
– Inhibitor or inductor of the No
cytochrome P450 system?
– Other significant pharmacokinetic None
interactions:
• Elimination of parent drug: Renal
• Typical therapeutic range: 5–30 mg/L (29.4–176 mmol/L)
• Potentially toxic concentration: )400 mg/L ()2350 mmol/L)
Pre-analytics
• Time to steady-state since beginning of ;2 days
treatment or change of posology:
• Time for blood sampling: Before next dose at steady-state
• Type(s) of sample: Serum or plasma
• Stability: 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2009.
• Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than
800 drugs and other xenobiotics. Pharmazie 2003;58:447–74.
• Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic
drugs: when is monitoring needed? Clin Pharmacokinet 2006;45:1061–75.
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Oxcarbazepine
General
• Class of the drug: Antiepileptics
• Synonym(s):
• Common trade name(s) in Germany: Trileptal, Apydan, Timox





• Indications for TDM: Individual dose adaptation, verification of compliance, side effects, suspicion of toxicity
• Protein binding: MHD: 40% (albumin)
• Elimination half-life: Oxcarbazepine: 1–3 h
MHD: 11–15 h
• Volume of distribution: Oxcarbazepine: 3–15 L/kg
MHD: 0.7 L/kg
• Metabolism:
– Main metabolic pathways: Hydroxylation
– Active metabolite(s)? Yes (MHD)
– Inhibitor or inductor of the Inhibitor of CYP2C19; inductor of CYP3A4
cytochrome P450 system?
– Other significant pharmacokinetic None
interactions:
• Elimination of parent drug: Oxcarbazepine: mainly hepatic
MHD: mainly renal
• Typical therapeutic range: Oxcarbazepine: 0.025–0.33 mg/L (0.1–1.3 mmol/L)
MHD: 7.6–20.3 mg/L (30–80 mmol/L)
• Potentially toxic concentration: Not known
Pre-analytics
• Time to steady-state since beginning of ;2 days
treatment or change of posology:
• Time for blood sampling: Before next dose at steady-state
• Type(s) of sample: Serum or plasma
• Stability: 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2009.
• Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800
drugs and other xenobiotics. Pharmazie 2003;58:447–74.
• Baselt R. Disposition of toxic drugs and chemicals in man. Foster City, CA:
Biomedical Publications, 2008.
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Phenytoin
General
• Class of the drug: Antiepileptics
• Synonym(s): Diphenylhydantoin
• Common trade name(s) in Germany: Zentropil, Phenhydan
• Conversion factors: mg/L=3.96smmol/L
mmol/L=0.252smg/L
Clinical pharmacology
• Indications for TDM: Individual dose adaptation, verification of compliance, side effects, suspicion of toxicity
• Protein binding: 90% (albumin)
• Elimination half-life: 20–60 h (concentration-dependent; increases at higher levels due to saturation of
metabolism)
• Volume of distribution: 0.5–0.8 L/kg
• Metabolism:
– Main metabolic pathways: Hydroxylation by CYP2C9 and CYP2C19 (main metabolite: p-hydroxy-diphenyl-
hydantoin) followed by glucuroconjugation
– Active metabolite(s)? No
– Inhibitor or inductor of the Inductor of cytochromes CYP2C9, CYP2C19, and CYP3A4/5
cytochrome P450 system?
– Other significant pharmacokinetic Numerous other interactions
interactions:
• Elimination of parent drug: Mainly hepatic
• Typical therapeutic range: 10–20 mg/L (40–80 mmol/L)
• Potentially toxic concentration: )20 mg/L ()80 mmol/L)
Pre-analytics
• Time to steady-state since beginning of 5–14 days (concentration-dependent)
treatment or change of posology:
• Time for blood sampling: Before next dose at steady-state
• Type(s) of sample: Serum or plasma
• Stability: 48 h at 48C
Remarks A small increase of the dose might produce a disproportional increase in plasma
concentration due to the nonlinear kinetics of phenytoin.
In case of hypoalbuminemia or diminished binding, the free fraction of phenytoin
increases.
Slow hydroxylators could develop toxic effects at a common posology.
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2009.
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie und Toxikologie,
Grundlagen der Arzneimitteltherapie (16. Auflage). Basel: Documed, 2005.
• http://pharmacoclin.hug-ge.ch/_library/pdf/cytp450.pdf. Accessed 15 January 2010.
• Vozeh S, Muir KT, Sheiner LB, Follath F. Predicting individual phenytoin dosage. J
Pharmacokinet Biopharm 1981;9:131–46.
• Neels HM, Sierens AC, Naelaerts K, Hatfield GM, Lambert WE. Therapeutic drug
monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004;42:1228–
55.
• Warner A, Privitera M, Bates D. Standards of laboratory practice: antiepileptic drug
monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998;44:1085–95.
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Primidone
General
• Class of the drug: Antiepileptics
• Synonym(s):
• Common trade name(s) in Germany: Mylepsinum





• Indications for TDM: Individual dose adaptation, verification of compliance, side effects, suspicion of
toxicity
• Protein binding: -20%
• Elimination half-life: Primidone: 5–16 h
Phenobarbital: 50–150 h
Phenylethylmalonamide: 16–50 h
Volume of distribution: 0.6 L/kg
Metabolism:
– Main metabolic pathways: CYP2C9 and CYP2C19
– Active metabolite(s)? Phenobarbital
Phenylethylmalonamide
– Inhibitor or inductor of the Inductor of cytochromes CYP2C9, CYP2C19, and CYP3A4
cytochrome P450 system?
– Other significant pharmacokinetic Numerous interactions, e.g., with other antiepileptics, oral anticoagulants, steroids
interactions:
• Elimination of parent drug: Hepatic: 17%–73%
Renal: 15%–65%
• Typical therapeutic range: Primidone: 5–12 mg/L (23–55 mmol/L)
Phenobarbital: 15–40 mg/L (64–172 mmol/L)
• Potentially toxic concentration: Primidone: )15 mg/L ()69 mmol/L)
Pre-analytics
• Time to steady-state since beginning of Primidone: 2 days
treatment or change of posology: Phenobarbital: 10–30 days
• Time for blood sampling: Before next dose at steady-state
• Type(s) of sample: Serum or plasma
• Stability: 48 h at 48C
Remarks TDM of primidone must include measurement of its main active metabolite
phenobarbital
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2009.
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie und Toxikologie,
Grundlagen der Arzneimitteltherapie (16. Auflage). Basel: Documed, 2005.
• Neels HM, Sierens AC, Naelaerts K, Hatfield GM, Lambert WE. Therapeutic drug
monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004;42:
1228–55.
• Warner A, Privitera M, Bates D. Standards of laboratory practice: antiepileptic drug
monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998;44:1085–
95.
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Topiramate
General
• Class of the drug: Antiepileptics
• Synonym(s):
• Common trade name(s) in Germany: Topamax, Topiramat-Jansen
• Conversion factors: mg/L=4.23smmol/L
mmol/L=0.236smg/L
Clinical pharmacology
• Indications for TDM: Individual dose adaptation, verification of compliance, side effects, suspicion of
toxicity
• Protein binding: 13%–17%
• Elimination half-life: 21 h
• Volume of distribution: 0.55–0.8 L/kg (lower in women than in men)
• Metabolism:
– Main metabolic pathways: Not known
– Active metabolite(s)? No
– Inhibitor or inductor of the Strong inductor of CYP3A4, strong inhibitor of CYP2C19
cytochrome P450 system?
– Other significant pharmacokinetic Not known
interactions:
• Elimination of parent drug: Mainly renal, hepatic 20% (50% if treated with other antiepileptics)
• Typical therapeutic range: 4.0–12.2 mg/L (16.9–51.6 mmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state since beginning of 4–5 days
treatment or change of posology:
• Time for blood sampling: Before next dose at steady-state
• Type(s) of sample: Serum or plasma
• Stability: 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2009.
• Bialer M. The pharmacokinetics and interactions of new antiepileptic drugs: an
overview. Ther Drug Monit 2005;27:722–6.
• http://www.kardiolab.ch/CYP450_2JSI.html.
• Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic
drugs: when is monitoring needed? Clin Pharmacokinet 2006;45:1061–75.
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Vigabatrin
General
• Class of the drug: Antiepileptics
• Synonym(s): Gamma-vinyl GABA
• Common trade name(s) in Germany: Sabril
• Conversion factors: mg/L=7.7smmol/L
mmol/L=0.130smg/L
Clinical pharmacology
• Indications for TDM: Verification of compliance
• Protein binding: No
• Elimination half-life: 5–8 h (elderly 12–13 h)
• Volume of distribution: 1.0–1.4 L/kg
• Metabolism:
– Main metabolic pathways: No metabolites identified
– Active metabolite(s)? No
– Inhibitor or inductor of the No
cytochrome P450 system?
– Other significant pharmacokinetic A gradual reduction of approximately 20%–30% in plasma phenytoin concentration has
interactions: been observed following add-on therapy with vigabatrin
• Elimination of parent drug: Mainly renal
• Typical therapeutic range: No direct correlation between concentration and effectiveness. Because vigabatrin
acts irreversibly, it would be unlikely to have a therapeutic range
• Potentially toxic concentration: Not known
Pre-analytics
• Time to steady-state since beginning of 2 days
treatment or change of posology:
• Time for blood sampling: Before next dose at steady-state
• Type(s) of sample: Serum or plasma
• Stability: 1 week at 48C
Remarks S-enantiomer pharmacologically active
Irreversible enzyme inhibition (GABA transaminase): half-life of the drug is clinically
not relevant
References • Kra¨mer G. Epilepsy in the elderly: clinical aspects and pharmacotherapy.
Stuttgart/New York: Thieme 1999:89–90.
• Arzneimittelkompendium Schweiz. Basel: Documed, 2009.
• Neels HM, Sierens AC, Naelarts K, Scharpe SL, Hatfield GM, Lambert WE.
Therapeutic drug monitoring of old and newer anti-apileptic drugs. Clin Chem Lab
Med 2004;42:1228–55.
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie und Toxikologie,
Grundlagen der Arzneimitteltherapie (16. Auflage). Basel: Documed, 2005.
• Schneble H, Ernst JP. Vademecum antiepilepticum 2003/2004 – Pharmakotherapie der
Epilepsien (17. Auflage). Kehl-Kolk: Deutsche Sektion der Internationalen Liga gegen
Epilepsie; pp. 66–67.
• Neurology, version 3. North Melbourne, Vic., Australia: Therapeutic Guidelines
Limited 2007. Available at: http://www.tg.com.au/
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